This company has been marked as potentially delisted and may not be actively trading. Histogenics (HSGX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock HSGX vs. APT, MLSS, LGMK, ETON, AQST, ITOS, KOD, VIGL, DCTH, and ATXSShould you be buying Histogenics stock or one of its competitors? The main competitors of Histogenics include Alpha Pro Tech (APT), Milestone Scientific (MLSS), LogicMark (LGMK), Eton Pharmaceuticals (ETON), Aquestive Therapeutics (AQST), iTeos Therapeutics (ITOS), Kodiak Sciences (KOD), Vigil Neuroscience (VIGL), Delcath Systems (DCTH), and Astria Therapeutics (ATXS). Histogenics vs. Its Competitors Alpha Pro Tech Milestone Scientific LogicMark Eton Pharmaceuticals Aquestive Therapeutics iTeos Therapeutics Kodiak Sciences Vigil Neuroscience Delcath Systems Astria Therapeutics Alpha Pro Tech (NYSE:APT) and Histogenics (NASDAQ:HSGX) are both small-cap surgical appliances & supplies industry companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Which has preferable earnings and valuation, APT or HSGX? Alpha Pro Tech has higher revenue and earnings than Histogenics. Histogenics is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlpha Pro Tech$58.18M0.88$4.19M$0.3712.73HistogenicsN/AN/A-$8.64M-$0.79-1.26 Do institutionals & insiders hold more shares of APT or HSGX? 22.7% of Alpha Pro Tech shares are owned by institutional investors. Comparatively, 40.4% of Histogenics shares are owned by institutional investors. 15.0% of Alpha Pro Tech shares are owned by company insiders. Comparatively, 19.7% of Histogenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is APT or HSGX more profitable? Alpha Pro Tech has a net margin of 6.99% compared to Histogenics' net margin of 0.00%. Alpha Pro Tech's return on equity of 6.70% beat Histogenics' return on equity.Company Net Margins Return on Equity Return on Assets Alpha Pro Tech6.99% 6.70% 5.76% Histogenics N/A -34.96%18.40% Does the media prefer APT or HSGX? In the previous week, Alpha Pro Tech had 4 more articles in the media than Histogenics. MarketBeat recorded 4 mentions for Alpha Pro Tech and 0 mentions for Histogenics. Alpha Pro Tech's average media sentiment score of 0.67 beat Histogenics' score of 0.00 indicating that Alpha Pro Tech is being referred to more favorably in the media. Company Overall Sentiment Alpha Pro Tech Positive Histogenics Neutral Which has more risk & volatility, APT or HSGX? Alpha Pro Tech has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Histogenics has a beta of 3.1, meaning that its stock price is 210% more volatile than the S&P 500. SummaryAlpha Pro Tech beats Histogenics on 8 of the 12 factors compared between the two stocks. Get Histogenics News Delivered to You Automatically Sign up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HSGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HSGX vs. The Competition Export to ExcelMetricHistogenicsSurgical Appliances & Supplies IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.45M$27.63M$5.44B$9.61BDividend YieldN/AN/A4.61%4.14%P/E Ratio-1.2612.7329.7624.84Price / SalesN/A2.31449.1298.65Price / CashN/A12.8036.4258.36Price / Book-99.842.238.185.64Net Income-$8.64M-$5.31M$3.26B$265.68M Histogenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HSGXHistogenicsN/A$1.00-0.2%N/A-21.9%$94.45MN/A-1.2649APTAlpha Pro Tech2.2494 of 5 stars$4.80-0.6%N/A-13.4%$52.15M$58.18M12.97120News CoverageMLSSMilestone Scientific2.0044 of 5 stars$0.49-1.1%$1.25+152.9%-30.8%$38.79M$8.61M-7.0630LGMKLogicMark0.2206 of 5 stars$0.00+24.2%N/A-99.9%$2.36M$9.88M0.0020Positive NewsUpcoming EarningsETONEton Pharmaceuticals1.9822 of 5 stars$14.52+0.6%$29.67+104.3%+373.5%$389.43M$39.01M-80.6720News CoverageEarnings ReportAnalyst DowngradeGap UpAQSTAquestive Therapeutics1.832 of 5 stars$3.92-0.3%$10.14+158.7%+18.5%$389.37M$57.56M-6.64160News CoverageUpcoming EarningsITOSiTeos Therapeutics2.9223 of 5 stars$10.12+0.1%$15.64+54.6%-32.5%$387.29M$35M-3.3390News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastKODKodiak Sciences3.1665 of 5 stars$7.30-6.4%$9.00+23.3%+222.4%$385.15MN/A-2.0190Upcoming EarningsGap UpVIGLVigil Neuroscience3.0946 of 5 stars$8.05-0.1%$10.80+34.2%N/A$383.88MN/A-3.9340News CoverageUpcoming EarningsDCTHDelcath Systems3.0173 of 5 stars$10.93+0.2%$24.00+119.6%+24.3%$380.69M$37.21M-21.8660News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionATXSAstria Therapeutics2.154 of 5 stars$6.73+1.2%$29.00+330.9%-36.9%$379.77MN/A-3.6030Upcoming Earnings Related Companies and Tools Related Companies APT Competitors MLSS Competitors LGMK Competitors ETON Competitors AQST Competitors ITOS Competitors KOD Competitors VIGL Competitors DCTH Competitors ATXS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HSGX) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogenics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Histogenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
